Literature DB >> 2212375

Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing cardiac transplantation.

E G Giardina1, M Schneider, M L Barr.   

Abstract

Myocardial amiodarone and desethylamiodarone concentrations were measured at multiple sites in the explanted heart in four patients who underwent cardiac transplantation. Patients were taking amiodarone, 200 to 400 mg/day (mean 300 +/- 115), for 88 to 428 days (mean 229 +/- 148). The mean cumulative dose was 58 +/- 21.3 g. Plasma amiodarone concentration in three subjects was 204, 312 and 419 ng/ml and desethylamiodarone concentration was 268, 513 and 880 ng/ml, respectively. Significant interindividual variability in myocardial concentrations of amiodarone and desethylamiodarone was observed (p less than 0.05). Mean myocardial amiodarone concentration ranged from 4 +/- 1.0 to 29 +/- 17.2 micrograms/g (p less than 0.05); mean desethylamiodarone concentration ranged from 22 +/- 8.8 to 141 +/- 102.5 micrograms/g (p less than 0.05). At each site, save for fat, myocardial desethylamiodarone concentration was higher than amiodarone concentration. Greater intraindividual variability was observed in myocardial desethylamiodarone compared with amiodarone concentration particularly in septal and scar tissue (p = NS). No significant relation was found between myocardial concentration and duration of treatment. In patients with significant ventricular disease, usefulness of plasma amiodarone and desethylamiodarone concentration to estimate myocardial concentration is limited by intra- and interindividual variability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2212375     DOI: 10.1016/s0735-1097(10)80346-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients.

Authors:  Douglas L Jennings; Brandon Martinez; Sheila Montalvo; David E Lanfear
Journal:  Heart Fail Rev       Date:  2015-09       Impact factor: 4.214

Review 3.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

4.  Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity.

Authors:  Carmelo Lafuente-Lafuente; Jean-Claude Alvarez; Antoine Leenhardt; Stéphane Mouly; Fabrice Extramiana; Charles Caulin; Christian Funck-Brentano; Jean-François Bergmann
Journal:  Br J Clin Pharmacol       Date:  2009-02-02       Impact factor: 4.335

5.  Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Hugo A Katus; Andreas O Doesch
Journal:  Drug Des Devel Ther       Date:  2017-06-19       Impact factor: 4.162

6.  Combined amiodarone and digitalis therapy before heart transplantation is associated with increased post-transplant mortality.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Ann-Kathrin Rahm; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Andreas O Doesch; Philipp Ehlermann; Hugo A Katus; Edgar Zitron
Journal:  ESC Heart Fail       Date:  2020-07-01

7.  Amiodarone Use Prior to Cardiac Transplant Impacts Early Post-Transplant Survival.

Authors:  Salman S Allana; Furqan A Rajput; Jason W Smith; Lucian Lozonschi; Jinn-Ing Liou; Maryl Johnson; Takushi Kohmoto; Ravi Dhingra
Journal:  Cardiovasc Drugs Ther       Date:  2020-10-19       Impact factor: 3.727

8.  Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Bastian Schmack; Christian Erbel; Christian A Gleissner; Mohammadreza Akhavanpoor; Lutz Frankenstein; Fabrice F Darche; Patrick A Schweizer; Dierk Thomas; Philipp Ehlermann; Tom Bruckner; Hugo A Katus; Andreas O Doesch
Journal:  Drug Des Devel Ther       Date:  2016-02-16       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.